An enzymatic synthesis method for (S)-1-cyclopropylethylamine

By utilizing amine dehydrogenase and glucose dehydrogenase to catalyze the reductive amination of cyclopropylmethyl ketone via a biocatalytic route, the problems of complex operation and low yield in the existing chemical synthesis of (S)-1-cyclopropylethylamine have been solved, achieving a synthesis with high optical purity and industrial potential.

CN123063476APending Publication Date: 2026-11-10杭州微远生物科技有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611291949.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-25
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing chemical methods for synthesizing (S)-1-cyclopropylethylamine suffer from problems such as complex operation, insufficient yield, difficulty in separating by-products, and low overall yield, and are not conducive to large-scale industrial production.

Method used

A biocatalytic approach was adopted, utilizing amine dehydrogenase and glucose dehydrogenase to catalyze the reductive amination of cyclopropylmethyl ketone. Through the synergistic effect of amine dehydrogenase AmDH-1 or its mutant and glucose dehydrogenase GDH, high optical purity (S)-1-cyclopropylethylamine was generated.

Benefits of technology

The synthesis of (S)-1-cyclopropylethylamine with high optical purity was achieved. The method is simple to operate, has mild reaction conditions, is environmentally friendly, and is suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063476A_ABST
    Figure CN123063476A_ABST
Patent Text Reader

Abstract

This invention discloses an enzymatic synthesis method for (S)-1-cyclopropylethylamine, using cyclopropylmethyl ketone as a substrate. The reaction is catalyzed by amine dehydrogenase and glucose dehydrogenase. After the reaction, the product is separated and purified to obtain (S)-1-cyclopropylethylamine. This invention enables the efficient synthesis of (S)-1-cyclopropylethylamine, producing a product with high optical purity, and offers significant economic benefits for its industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biosynthesis technology, and in particular to an enzymatic method for the synthesis of (S)-1-cyclopropylethylamine. Background Technology

[0002] (S)-1-Cyclopropylethylamine is a high-optical-purity chiral primary amine whose molecular structure contains a cyclopropane ring and a chiral center. Due to its unique structural characteristics, this compound is widely used as an important chiral building block in organic synthesis, and it has particularly wide-ranging applications in medicinal chemistry research.

[0003] Cyclopropylalkylamine compounds can be prepared according to reported synthetic methods and further obtained by conventional chemical transformation to substituted derivatives containing a pyrazinone ring. These substituted pyrazinone compounds can serve as key intermediates for the synthesis of pharmaceutically active molecules with a pyrazinone core, such as RORγ modulators. Multiple signaling pathways mediated by the RORγ receptor are closely related to the development and progression of various diseases; therefore, these modulators can be used to treat related diseases, including but not limited to psoriasis and other inflammatory diseases.

[0004] (S)-1-Cyclopropylethylamine: As an important pharmaceutical intermediate, 1-cyclopropylethylamine is mainly prepared by chemical methods. One method is the Raney nickel-catalyzed hydrogenation reduction method, which reacts cyclopropyl methyl ketone with ammonia in the presence of a Raney nickel catalyst to prepare 1-cyclopropylethylamine. The main problems with this method are: the Raney nickel activation method is complex, there is a possibility of spontaneous combustion, and the yield is insufficient. In addition, cyclopropyl groups are prone to ring-opening reactions in the presence of transition metal complexes, generating byproducts that are difficult to separate. Furthermore, CN112930336A also discloses a method for preparing (S)-1-cyclopropylethyl-1-amine by chiral resolution-reductive amination. This method uses cyclopropyl methyl ketone and the chiral resolving agent S-(-)-α-phenylethylamine as raw materials, and prepares the target product through a reductive amination reaction. However, this method has a long route, cumbersome operation steps, and requires the use of chiral resolving reagents, resulting in a low overall yield, poor atom economy, and is not conducive to large-scale industrial production. Summary of the Invention

[0005] The purpose of this invention is to provide an enzymatic synthesis method for (S)-1-cyclopropylethylamine, which adopts a biocatalytic route and has the advantages of high optical purity of the product, simple operation steps, mild reaction conditions, and environmental friendliness.

[0006] The technical solution adopted by this invention to solve its technical problem is: An enzymatic synthesis method for (S)-1-cyclopropylethylamine involves using cyclopropylmethyl ketone as a substrate, followed by a reaction catalyzed by amine dehydrogenase and glucose dehydrogenase. After the reaction is completed, the reaction product is separated and purified to obtain (S)-1-cyclopropylethylamine. The amine dehydrogenase is derived from *Thermophyton floccosum* SJ95 (… Petrotogamobilis SJ95 amine dehydrogenase Am DH-1 or amine dehydrogenase Am DH-1 mutant, amine dehydrogenase Am The amino acid sequence of DH-1 is shown in SEQ ID NO.2.

[0007] This invention develops a novel route for the reductive amination of cyclopropylmethyl ketone to (S)-1-cyclopropylethylamine using amine dehydrogenase-catalyzed reduction. Figure 1 As shown in the figure, the synthesis process itself is highly feasible. The inventors, through research, discovered that... Petrotogamobilis SJ95 Amine dehydrogenase from Am Using DH-1 or its mutant as a catalyst, cyclopropylmethyl ketone can be efficiently reduced to (S)-1-cyclopropylethylamine. This invention enables the efficient synthesis of (S)-1-cyclopropylethylamine, producing a product with high optical purity, and offers significant economic benefits for its industrial production.

[0008] Preferably, the amine dehydrogenase Am DH-1 mutants are selected from one of the following: Am DH-1-V134L / T303A: The amino acid sequence shown in SEQ ID NO.2 has a V mutation at position 134, which is changed to L, and a T mutation at position 303, which is changed to A; Am DH-1-V134L / F168A: The amino acid sequence shown in SEQ ID NO.2 has a V mutation at position 134, which is changed to L, and an F mutation at position 168, which is changed to A; Am DH-1-V134L / Q176L: The amino acid sequence shown in SEQ ID NO.2 has a V mutation at position 134, which is changed to L, and a Q mutation at position 176, which is changed to L. Am DH-1-V134L / I198V: The amino acid sequence shown in SEQ ID NO.2 has a V mutation at position 134, which is changed to L, and an I mutation at position 198, which is changed to V; Am DH-1-F168A / T303A: The F at position 168 of the amino acid sequence shown in SEQ ID NO.2 is mutated to A, and the T at position 303 is mutated to A; AmDH-1-F168A / Q176L: The amino acid sequence shown in SEQ ID NO.2 has an F mutation at position 168, which is changed to A, and a Q mutation at position 176, which is changed to L; Am DH-1-F168A / I198V: The amino acid sequence shown in SEQ ID NO.2 has an F mutation at position 168, which is changed to A, and an I mutation at position 198, which is changed to V; Am DH-1-T303A / Q176L: The amino acid sequence shown in SEQ ID NO.2 has a T mutation at position 303 to A, and a Q mutation at position 176 to L; Am DH-1-T303A / I198V: The amino acid sequence shown in SEQ ID NO.2 has a T mutation at position 303 that is changed to A, and an I mutation at position 198 that is changed to V; Am DH-1-Q176L / I198V: The amino acid sequence shown in SEQ ID NO.2 has a Q mutation at position 176 to L, and an I mutation at position 198 to V.

[0009] Preferably, the glucose dehydrogenase is derived from *Priscilla megaterium* (…). Priestiamegaterium ) glucose dehydrogenase GDH.

[0010] The amine dehydrogenase Am DH-1 or amine dehydrogenase Am The DH-1 mutant was added in the form of pure enzyme, crude enzyme solution, immobilized enzyme, immobilized cells, or wet cells of recombinant genetically engineered bacteria.

[0011] The composition of the raw materials in the enzyme-catalyzed reaction system is as follows: substrate cyclopropyl methyl ketone 20-80 g / L, expressing amine dehydrogenase. Am DH-1 or amine dehydrogenase Am 10-40 g / L of wet cells of recombinant E. coli expressing DH-1 mutant, 10-40 g / L of wet cells of recombinant E. coli expressing glucose dehydrogenase, 0.1 mM-1.5 mM of NADH, 0.4 M-1.5 M of glucose, and the balance of buffer.

[0012] Preferably, the buffer solution is an ammonium chloride / ammonia water buffer solution with a pH of 7.0-9.0.

[0013] Preferably, the temperature of the enzyme-catalyzed reaction is 30-50℃, and the reaction time is 4-14h.

[0014] As a preferred embodiment, the nucleotide sequence of glucose dehydrogenase is shown in SEQ ID NO:8.

[0015] The beneficial effects of this invention are: This invention can efficiently catalyze the reduction and amination of cyclopropylmethyl ketone at a concentration of 20-80 g / L to obtain (S)-1-cyclopropylethylamine with an optical purity of 99.5%, demonstrating good potential for industrial application and economic benefits. Attached Figure Description

[0016] Figure 1 This is a process route diagram of the present invention; Figure 2 It is an amine dehydrogenase Am The activity of DH-1-V134L / T303A varies at different temperatures and pH levels; Figure 3 This is a gas phase detection result of the purity of (S)-1-cyclopropylethylamine. Detailed Implementation

[0017] The technical solution of the present invention will be further described in detail below through specific embodiments.

[0018] In this invention, unless otherwise specified, all raw materials and equipment used are commercially available or commonly used in the field. The methods described in the following embodiments are conventional methods in the field, unless otherwise specified.

[0019] The catalytic process flow of this invention is as follows: Figure 1 As shown. Utilizing amine dehydrogenase Am DH-1 reduces and aminations cyclopropylmethyl ketone to (S)-1-cyclopropylethylamine. The preparation of the amine dehydrogenases used in this invention follows standard biological procedures, and *Escherichia coli* can be selected as the host microorganism for protein expression. Escherichia coli BL21(DE3) can be used as the recombinant plasmid, and pET28 plasmid can be selected. The molecular biology operations involved are all well-known and routine experimental procedures in the biological field, including gene acquisition (PCR), splicing of plasmids and target genes (i.e., vector construction), introduction of plasmids containing the target gene fragment into bacterial cells (i.e., transformation), and bacterial culture and enzyme production in the culture medium (i.e., fermentation). In this invention, the LB liquid culture medium formula is: 10 g / L tryptone, 5 g / L yeast extract, and 10 g / L NaCl; the LB solid culture medium formula is: 10 g / L tryptone, 5 g / L yeast extract, 10 g / L NaCl, and 20 g / L agar.

[0020] Example 1: Preparation of recombinant genetically engineered bacteria containing amine dehydrogenase This invention uses amine dehydrogenases from different sources for comparison. The synthesis of the complete genome and the construction of the recombinant plasmid were completed by Beijing Qingke Biotechnology Co., Ltd., and the amine dehydrogenases were compared. Am DH - 1. Am DH- 2 , Am DH - 3 , Am DH - 4 , Am DH - 5. Am DH - The gene for gene 6 underwent codon optimization (the optimized gene sequence is shown in Table 1). Corresponding restriction enzyme sites (NcoI and NotI) were added to both ends of the gene, and the resulting structure was constructed into the pET28a plasmid vector to obtain a recombinant plasmid vector for amine dehydrogenase. After sequencing verification, the recombinant plasmid vector for amine dehydrogenase was transformed into *E. coli* BL21(DE3) to obtain recombinant genetically engineered bacteria. E. coli BL21(DE3) / pET28a- Am DH - 1. E. coli BL21(DE3) / pET28a- Am DH - 2 , E. coli BL21(DE3) / pET28a- Am DH - 3 , E. coli BL21(DE3) / pET28a- Am DH - 4 , E. coli BL21(DE3) / pET28a- Am DH - 5. E. coli BL21(DE3) / pET28a- Am DH - 6. The source and gene sequence of the amine dehydrogenase of this invention are shown in Table 1. Am DH - The amino acid sequence of 1 is shown in SEQ ID NO:2. The recombinant genetically engineered bacteria were verified to correctly express the target protein.

[0021] Table 1 Sources of amine dehydrogenases .

[0022] Example 2: Preparation of recombinant Escherichia coli wet cells expressing amine dehydrogenase Recombinant genetically engineered bacteria E. coli BL21(DE3) / pET28a- Am DH - 1. E. coli BL21(DE3) / pET28a- Am DH - 2 , E. coli BL21(DE3) / pET28a-Am DH - 3 , E. coli BL21(DE3) / pET28a- Am DH - 4 、 E. coli BL21(DE3) / pET28a- Am DH - 5. E. coli BL21(DE3) / pET28a- Am DH - 6. Inoculate separately into LB liquid medium containing 50 μg / mL kanamycin and incubate overnight at 37°C. Then, inoculate 2% (v / v) into LB liquid medium containing 50 μg / mL kanamycin and incubate at 37°C and 150 rpm until the bacterial cell concentration reaches OD600. 600 =Approximately 0.6, add IPTG to a final concentration of 0.1mM, induce culture at 20℃ for 15h, then centrifuge at 4℃ and 12000rpm for 10min to collect wet cells. Wash the wet cells with 0.85% physiological saline and store at -20℃ for later use (i.e., resting cells, used for the reaction).

[0023] Example 3: Preparation of recombinant wet Escherichia coli expressing GDH Will come from Priestiamegaterium After codon optimization of the glucose dehydrogenase gene (the nucleotide sequence of GDH is shown in SEQ ID NO:8), corresponding restriction enzyme sites (NcoI and NotI) were added to both ends of the gene, and the resulting recombinant plasmid vector, pET28a, was constructed into the glucose dehydrogenase vector (completed by Beijing Qingke Biotechnology Co., Ltd.). After sequencing verification, the recombinant plasmid vector was transformed into *E. coli* BL21(DE3) and plated on LB agar plates containing kanamycin (50 mg / L) resistance. The plates were incubated at 37°C for 12 hours to obtain the recombinant genetically engineered bacterium *E. coli* BL21(DE3) / pET28a-GDH. The recombinant genetically engineered bacterium was verified to correctly express the target protein.

[0024] Recombinant genetically engineered bacteria E. coli BL21(DE3) / pET28a-GDH was inoculated into LB liquid medium containing 50 μg / mL kanamycin and incubated overnight at 37°C. Then, it was inoculated at a 2% (v / v) inoculation rate into LB liquid medium containing 50 μg / mL kanamycin and incubated at 37°C and 150 rpm until the bacterial concentration reached OD500. 600=Approximately 0.6, add IPTG to a final concentration of 0.1mM, induce culture at 20℃ for 12h, then centrifuge at 4℃ and 12000rpm for 10min to collect wet cells. Wash the wet cells with 0.85% physiological saline and store at -20℃ for later use (i.e., resting cells, used for the reaction).

[0025] Example 4: Reductive amination of cyclopropylmethyl ketone catalyzed by recombinant Escherichia coli with amine dehydrogenase The amine dehydrogenase prepared in Example 2 Am DH - 1. Am DH - 2 , Am DH - 3 , Am DH - 4 , Am DH - 5 and Am DH - Using recombinant Escherichia coli wet cells (Example 6) and GDH-expressing recombinant Escherichia coli wet cells (Example 3) as catalysts, 40 g / L cyclopropyl methyl ketone was used to catalyze a 20 mL reaction system containing: 0.8 g cyclopropyl methyl ketone (Shanghai Mairui Biochemical Technology Co., Ltd.), 1.0 mM NADH, 1.0 M glucose, 0.2 g GDH-expressing recombinant Escherichia coli wet cells, and amine dehydrogenase expression. Am DH - 1. Am DH - 2 , Am DH - 3 , Am DH - 4 , Am DH - 5 and Am DH - 0.8 g of each recombinant *E. coli* wet cell was added to a final volume of 20 mL with ammonium chloride / ammonia buffer (100 mM, pH 7.5). The purity of the product (S)-1-cyclopropylethylamine was determined by gas chromatography. The 1H NMR spectrum of the product (S)-1-cyclopropylethylamine was as follows: 1H NMR (400 MHz, CDCl3) δ 0.60 - 0.65 (m, 2H), 0.85 - 0.95 (m, 2H), 1.07 (d, J = 6.6 Hz, 3H), 1.68 - 1.75 (m, 1H), 2.81 (q, J = 6.6 Hz, 1H).

[0026] As shown in Table 2, the reaction time was 12 hours, and the concentration was 40 g / L. Am DH -1 can completely catalyze the reductive amination of 40 g / L cyclopropanemethyl ketone with a conversion rate >99%, while the activity of other amine dehydrogenases to cyclopropanemethyl ketone is low.

[0027] Table 2. Reduction reactions of cyclopropylmethyl ketone catalyzed by different amine dehydrogenases .

[0028] Example 5: Am DH-1 Vitality Modification Based on the results of the above embodiments, Am DH-1 was used as the original template to prepare Am The specific steps for the DH-1 mutant are as follows.

[0029] (1) Constructing a single mutant library: Take the sample prepared in Example 1 above. Am DH-1 recombinant genetically engineered bacteria, from which plasmid (pET28a-) was extracted. Am DH-1). (with pET28a-) Am Using DH-1 as a template, mutant primers were designed (as shown in Table 3 below) for polymerase chain reaction (PCR). The PCR amplification system (50 µL) is shown in Table 4, and the amplification product was obtained. Then, 20 µL of the PCR product was digested with 1 µL of restriction enzyme Dpn I at 37°C for 3 h to remove the template plasmid DNA, and then inactivated at 65°C for 10 min. The recombinant plasmid was heat-shocked and transformed into E. coli BL21(DE3) competent cells, and the clones were inoculated into 10 mL LB agar plates and cultured at 37°C for 12–16 h.

[0030] Table 3. Mutant Primers .

[0031] Table 4. PCR amplification system (50µL) .

[0032] The PCR amplification program followed the Phanta Super-Fidelity DNA polymerase (Novizan) instructions: 95℃ pre-denaturation for 5 min; 95℃ denaturation for 15 s, 66℃ annealing for 15 s, 72℃ extension for 5 min, for 30 cycles; then 72℃ final extension for 10 min, and incubation at 16℃.

[0033] Then, positive clones and the original bacterial strain were randomly selected from the plates and inoculated into 10 mL of LB liquid medium (containing 50 mg / L kanamycin) and cultured at 37°C and 200 rpm in a shaker for 8-10 h. The culture was then inoculated at a 1% inoculation rate into 100 mL of LB liquid medium (containing 50 mg / L kanamycin) and cultured at 37°C and 180 rpm in a shaker for 2-2.5 h (OD600 value 0.6-0.8). Then, IPTG inducer was added to a final concentration of 0.1 mM, and the mixture was cultured for another 15 h at 20°C and 180 rpm in a shaker. Finally, the cultured bacterial solution was transferred to a 500 mL centrifuge cup and centrifuged at 8000 rpm and 4°C for 10 min in a low-temperature high-speed centrifuge. The supernatant was discarded, and the bacterial cells were collected and weighed.

[0034] Obtaining a single mutant Am DH-1-V134L Am DH-1-F168A Am DH-1-T303A, Am DH-1-Q176L and Am DH-1-I198V.

[0035] The transformation effect of each mutant on cyclopropyl methyl ketone was tested using the method described in Example 4 above. Dominant strains were screened based on transformation rate and optical purity. The obtained dominant strains were sent to Hangzhou Qingke Biotechnology Co., Ltd. for sequencing to confirm the mutation status.

[0036] (2) Iterative mutation (constructing multiple mutants): The results obtained from the above steps Am DH-1-V134L Am DH-1-F168A Am DH-1-T303A, Am DH-1-Q176L and Am Plasmids were extracted from DH-1-I198V recombinant bacteria. Using the extracted plasmids as templates, PCR amplification was performed using the mutant primers shown in Table 5 (system as in Table 4). Recombinant bacteria were constructed according to the method in step (1). The resulting multiple mutants included: Am DH-1-V134L / F168A Am DH-1-V134L / T303A Am DH-1-V134L / Q176L Am DH-1-V134L / I198V Am DH-1-F168A / T303A, Am DH-1-F168A / Q176L AmDH-1-F168A / I198V Am DH-1-T303A / Q176L Am DH-1-T303A / I198V and Am DH-1-Q176L / I198V.

[0037] (3) Catalytic activity detection: Using cyclopropylmethyl ketone as a substrate, the catalytic activity of the prepared single mutant, multiple mutants and original strain was detected, and the catalytic activity of each mutant was compared.

[0038] Specifically, the reaction system was set up as follows: 0.8 g cyclopropyl methyl ketone, 1.0 mM NADH, 1.0 M glucose, 0.2 g of wet recombinant E. coli expressing GDH, and... Am 0.4 g of recombinant E. coli wet cells of DH-1 mutant were added, and ammonium chloride / ammonia buffer (100 mM, pH 7.5) was added to a final volume of 20 mL. The catalytic reaction was carried out at 40 °C for 8 h. 1 mL of each sample was taken, and the conversion rate and optical purity were determined by GC.

[0039] The screening results are shown in Table 5. Further screening yielded the final results. Am The dominant strain of DH-1 mutant is Am DH-1-V134L / T303A.

[0040] Table 5. Conversion rate and optical purity of different mutants .

[0041] Example 6: Optimization of Reaction Temperature Add 0.8 g of cyclopropyl methyl ketone, 1.0 mM NADH, 1.0 M glucose, and 0.2 g of wetted recombinant E. coli expressing GDH to the reaction flask. Figure 2 0.4 g of recombinant *E. coli* cells (DH-1-V134L / T303A) were added to a final volume of 20 mL with ammonium chloride / ammonia buffer (100 mM, pH 7.5). Samples were collected after incubation at 25, 30, 35, 40, 45, 50, and 55 °C for 8 h for gas chromatography analysis. The results are as described above. Am As shown in a, Am DH-1-V134L / T303A exhibits the highest activity at 40℃, and 40℃ was selected as the optimal temperature for subsequent studies.

[0042] Example 7: Optimization of reaction pH Add 0.8 g of cyclopropyl methyl ketone, 1.0 mM NADH, 1.0 M glucose, and 0.2 g of wet recombinant E. coli expressing GDH to the reaction flask. Figure 20.4 g of recombinant *E. coli* cells (DH-1-V134L / T303A) were added to a final volume of 20 mL with ammonium chloride / ammonia buffer (100 mM, pH 7.5). The buffer was then replaced, and the mixtures were reacted for 8 hours in pH 7.0 phosphate buffer, pH 8.0 ammonium chloride / ammonia buffer, pH 8.5 ammonium chloride / ammonia buffer, pH 9.0 ammonium chloride / ammonia buffer, pH 9.5 glycine-NaOH buffer, and pH 10.0 glycine-NaOH buffer, respectively. Samples were then taken for gas chromatography analysis. The results are as described above. Am As shown in b. Am DH-1-V134L / T303A exhibited the highest activity at pH 7.5, and pH 7.5 was subsequently selected as the optimal pH for further research.

[0043] Example 8: Am Optimization of DH-1-V134L / T303A catalytic system Add 0.8 g of cyclopropyl methyl ketone, 1.0 mM NADH, 1.0 M glucose, and 0.2 g of wetted recombinant E. coli expressing GDH to the reaction flask. Am 0.4 g of recombinant Escherichia coli wet cells of DH-1-V134L / T303A were added to a final volume of 20 mL with ammonium chloride / ammonia buffer (100 mM, pH 7.5). After incubation at 40 °C for 8 h, samples were taken for gas chromatography analysis.

[0044] Single-factor substitutions should be performed according to the following conditions: Table 6 Am Optimization of DH-1-V134L / T303A catalytic system .

[0045] Example 9: Using expression of amine dehydrogenase Am DH - The recombinant Escherichia coli wet cell catalyzing the synthesis of (S)-1-cyclopropylethylamine from cyclopropylmethyl ketone by the 1-V134L / T303A mutant. Using the expression of amine dehydrogenase Am DH - (S)-1-cyclopropylethylamine was prepared by a 10 L scale-up reaction using recombinant Escherichia coli wet cells of the 1-V134L / T303A mutant. The reaction system was as follows: 10 L of ammonium chloride / ammonia buffer (100 mM, pH 7.5), 800 g of cyclopropylmethyl ketone, and expression of amine dehydrogenase. Figure 3 DH - 200 g of recombinant Escherichia coli wet cells of the 1-V134L / T303A mutant, 100 g of recombinant Escherichia coli wet cells expressing glucose dehydrogenase GDH, 1 mM NADH, and 0.8 M glucose.

[0046] The catalytic reaction was terminated by adding hydrochloric acid after reacting at 40℃ for 12 h. The mixture was centrifuged at 12000 rpm for 10 min to remove E. coli cells. The pH of the aqueous phase was adjusted to 10⁻¹² using NaOH. The product (S)-1-cyclopropylethylamine was extracted with ethyl acetate three times. After rotary evaporation of the organic phase, crude (S)-1-cyclopropylethylamine was obtained. The scale-up reaction yielded 660.8 g of purified (S)-1-cyclopropylethylamine, with a yield of 82.6%, a purity of 99.3%, and an optical purity of 99.5%. ​ ).

[0047] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the present invention in any way. Other variations and modifications are possible without departing from the technical solutions described in the claims.

[0048] Sequence information: SEQ ID NO.1: SEQ ID NO.2: MYKVGIWGFGAMGSGIAKNILSKKNLKLVGVHDFREEYIEKDVGELLGLGKIGIKVYPDPITMVKQTDPDLVVIATNSFISVVKDQIISILKENKNVITIAEEMAFPFSKDPKAANEIDTVAKDHNVSVLGTGVVPGFVLDTLIITLTGICLNVQRIKAAMIVDLSPFGPTVMETQGVGTTPEEFKQGIKSGKIVGHIGFEQSIHMIAKALGWEIDRIEQKREPIISNVMRETKYVKVQPGMVAGCNHTAKAFYKNELLIELELPQQVLPHLENVQTGDYITIQGDPDISMGINPEIPGGKGTIAIATNMIPSVVEARPGLLTMVDLPIPRALLAEVH; SEQ ID NO.3: SEQ ID NO.4: SEQ ID NO.5: SEQ ID NO.6: SEQ ID NO.7: SEQ ID NO.8: ATGTACAAAGATTTGGAAGGTAAAGTGGTTGTTATCACCGGCAGCTCCACTGGTCTGGGTAAAGCGATGGCAATCCGCTTTGCGACCGAAAAAGCGAAAGTTGTGGTGAACTACCGTTCCAAAGAAGAAGAAGCGAACTCTGTTCTGGAAGAGATCAAGAAAGTGGGTGGTGAAGCTATCGCTGTGAAAGGTGACGTTACCGTTGAATCTGACGTGATCAACCTGGTTCAAAGCTCCATCAAAGAGTTCGGTAAACTGGACGTGATGATCAACAACGCAGGTATGGAGAATCCGGTTTCTAGCCACGAAATGTCTCTGTCTGACTGGAACAAAGTTATCGACACCAACCTGACTGGTGCGTTTCTGGGTTCTCGTGAAGCGATCAAATACTTCGTTGAGAACGACATCAAAGGCACCGTTATCAACATGTCTAGCGTTCATGAGAAGATTCCGTGGCCGCTGTTCGTTCACTACGCGGCTTCTAAAGGCGGTATGAAACTGATGACTGAAACTCTGGCACTGGAATACGCTCCGAAAGGTATCCGTGTTAACAACATCGGTCCAGGTGCGATCAACACTCCGATCAACGCGGAGAAATTCGCTGACCCGGAACAGCGTGCAGACGTTGAATCCATGATTCCAATGGGTTACATCGGTGAACCGGAAGAAATCGCGGCGGTTGCTGCATGGCTGGCTTCTTCCGAAGCGTCTTACGTTACTGGTATCACCTTGTTCGCGGATGGTGGTATGACTCAGTATCCGAGCTTCCAGGCAGGTCGTGGTTAA。

Claims

1. An enzymatic method for the synthesis of (S)-1-cyclopropylethylamine, characterized in that, Using cyclopropylmethyl ketone as a substrate, the reaction was catalyzed by amine dehydrogenase and glucose dehydrogenase. After the reaction was completed, the reaction product was separated and purified to obtain (S)-1-cyclopropylethylamine. The amine dehydrogenase is derived from *Thermophyton floccosum* SJ95. Am DH-1 or amine dehydrogenase Am DH-1 mutant, amine dehydrogenase Am The amino acid sequence of DH-1 is shown in SEQ ID NO.

2.

2. The enzymatic synthesis method according to claim 1, characterized in that, The amine dehydrogenase Am DH-1 mutants are selected from one of the following: Am DH-1-V134L / T303A: The amino acid sequence shown in SEQ ID NO.2 has a V mutation at position 134, which is changed to L, and a T mutation at position 303, which is changed to A; Am DH-1-V134L / F168A: The amino acid sequence shown in SEQ ID NO.2 has a V mutation at position 134, which is changed to L, and an F mutation at position 168, which is changed to A; Am DH-1-V134L / Q176L: The amino acid sequence shown in SEQ ID NO.2 has a V mutation at position 134, which is changed to L, and a Q mutation at position 176, which is changed to L. Am DH-1-V134L / I198V: The amino acid sequence shown in SEQ ID NO.2 has a V mutation at position 134, which is changed to L, and an I mutation at position 198, which is changed to V; Am DH-1-F168A / T303A: The F at position 168 of the amino acid sequence shown in SEQ ID NO.2 is mutated to A, and the T at position 303 is mutated to A; Am DH-1-F168A / Q176L: The amino acid sequence shown in SEQ ID NO.2 has an F mutation at position 168, which is changed to A, and a Q mutation at position 176, which is changed to L; Am DH-1-F168A / I198V: The amino acid sequence shown in SEQ ID NO.2 has an F mutation at position 168, which is changed to A, and an I mutation at position 198, which is changed to V; Am DH-1-T303A / Q176L: The amino acid sequence shown in SEQ ID NO.2 has a T mutation at position 303 to A, and a Q mutation at position 176 to L; Am DH-1-T303A / I198V: The amino acid sequence shown in SEQ ID NO.2 has a T mutation at position 303, which is changed to A, and an I mutation at position 198, which is changed to V; Am DH-1-Q176L / I198V: The amino acid sequence shown in SEQ ID NO.2 has a Q mutation at position 176 to L, and an I mutation at position 198 to V.

3. The enzymatic synthesis method according to claim 1, characterized in that, The glucose dehydrogenase is glucose dehydrogenase GDH derived from Priestella megaterium.

4. The enzymatic synthesis method according to claim 1, 2, or 3, characterized in that, The amine dehydrogenase Am DH-1 or amine dehydrogenase Am The DH-1 mutant was added in the form of pure enzyme, crude enzyme solution, immobilized enzyme, immobilized cells, or wet cells of recombinant genetically engineered bacteria.

5. The enzymatic synthesis method according to claim 1, 2, or 3, characterized in that, The composition of the raw materials in the enzyme-catalyzed reaction system is as follows: substrate cyclopropyl methyl ketone 20-80 g / L, expressing amine dehydrogenase. Am DH-1 or amine dehydrogenase Am 10-40 g / L of wet cells of recombinant Escherichia coli with DH-1 mutant, 10-40 g / L of wet cells of recombinant Escherichia coli expressing glucose dehydrogenase, 0.1 mM-1.5 mM of NADH, 0.4 M-1.5 M of glucose, and the balance of buffer.

6. The enzymatic synthesis method according to claim 5, characterized in that, The buffer solution is an ammonium chloride / ammonia water buffer solution with a pH of 7.0-9.

0.

7. The enzymatic synthesis method according to claim 5, characterized in that, The temperature for enzyme-catalyzed reactions is 30-50℃, and the reaction time is 4-14h.

8. The enzymatic synthesis method according to claim 1, 2, or 3, characterized in that, The nucleotide sequence of glucose dehydrogenase is shown in SEQ ID NO:8.